EXUMA Biotech Announces Phase 1 Results for its Autologous HER2 Directed, Tumor Metabolism Regulated (TMR) CAR-T Product at ASCO GI 2025
Press Releases
EXUMA Biotech, Corp.  
January 23, 2025

EXUMA Biotech Announces Phase 1 Results for its Autologous HER2 Directed, Tumor Metabolism Regulated (TMR) CAR-T Product at ASCO GI 2025

No dose-limiting toxicities, severe adverse events, or on-target off-tumor toxicities across all dose cohorts

avatar profile Olean Times Herald

Olean Times Herald


Local & Social